Vol 60, No 1 (2009)
Review paper
Submitted: 2013-02-15
Published online: 2008-12-19
Mitogenic potency of insulin glargine
Katarzyna Żełobowska, Janusz Gumprecht, Władysław Grzeszczak
DOI: 10.5603/ep.25506
·
Endokrynol Pol 2009;60(1):34-39.
Vol 60, No 1 (2009)
Review Article
Submitted: 2013-02-15
Published online: 2008-12-19
Abstract
The goal of diabetes mellitus treatment is to maintain long-term near-normoglycaemia to prevent the onset or progression of long-term
complications. In order to achieve tight glycaemic control and improve the quality of life for diabetic patients, a number of novel insulin
preparations, insulin analogues, have been constructed thanks to recombinant DNA technologies and advanced protein chemistry. Because
structurally modified insulins may differ from human insulin not only in metabolic but also in mitogenic potencies there were
concerns raised about the possibility of increased insulin analogue proliferative action or tumourigenesis. In vitro and in vivo studies on
insulin analogues in comparison to endogenous insulin have been performed to closely monitor the insulin analogue action profiles.
Insulin glargine was the only one presenting a significant increase in affinity to insulin-like growth factor type 1 (IGF-1) receptor. However,
there was controversy regarding the safety of insulin glargine use because of its potential risk of mitogenicity but it proved to be true
only for human osteosarcoma cells Saos/B10. Outcomes of the studies performed on lines other than cancer cells and on animals did not
present any increased mitogenic activity nor mitogenic potency of insulin glargine in comparison to human insulin.
Abstract
The goal of diabetes mellitus treatment is to maintain long-term near-normoglycaemia to prevent the onset or progression of long-term
complications. In order to achieve tight glycaemic control and improve the quality of life for diabetic patients, a number of novel insulin
preparations, insulin analogues, have been constructed thanks to recombinant DNA technologies and advanced protein chemistry. Because
structurally modified insulins may differ from human insulin not only in metabolic but also in mitogenic potencies there were
concerns raised about the possibility of increased insulin analogue proliferative action or tumourigenesis. In vitro and in vivo studies on
insulin analogues in comparison to endogenous insulin have been performed to closely monitor the insulin analogue action profiles.
Insulin glargine was the only one presenting a significant increase in affinity to insulin-like growth factor type 1 (IGF-1) receptor. However,
there was controversy regarding the safety of insulin glargine use because of its potential risk of mitogenicity but it proved to be true
only for human osteosarcoma cells Saos/B10. Outcomes of the studies performed on lines other than cancer cells and on animals did not
present any increased mitogenic activity nor mitogenic potency of insulin glargine in comparison to human insulin.
Keywords
insulin analogue; glargine; mitogenicity
Title
Mitogenic potency of insulin glargine
Journal
Endokrynologia Polska
Issue
Vol 60, No 1 (2009)
Article type
Review paper
Pages
34-39
Published online
2008-12-19
Page views
535
Article views/downloads
1635
DOI
10.5603/ep.25506
Bibliographic record
Endokrynol Pol 2009;60(1):34-39.
Keywords
insulin analogue
glargine
mitogenicity
Authors
Katarzyna Żełobowska
Janusz Gumprecht
Władysław Grzeszczak
About this article
